Peter, this are
"comprehensive prognostic system of *pretreatment* clinical parameters"
and overall survival relative to *pretreatment* risk factor.
However, they did not say anything about group (inside risk factors) who were progressive after immunotherapy, have measurable metastatic disease and short life expectation. I am sure that median overals survival for this group (and for all risk factor subgroup) will go down.
My question is why pts entered this trial when they have 50% chance to get drug, without clear evidence that drug will be effective, and without any other option? With knowledge that their median survival on placebo will be, let say, 8-10 months? Is there any supportive care? After failing imuno-drug they can still try combination of the chemo-immuno, new modality drugs, vaccines, something,.. but not sugar pill. Check NCI, there is plenty ongoing RCC trials.
Now, can we trust this trial and assume that everything is according to protocol?? I can not!
If it is yes, than Neovastat have excellent result.
Miljenko |
